Novel blood-based biomarkers for dementia could identify disease at an early preclinical stage, serve as surrogate outcomes for clinical trials of investigational therapies and even identify future potential therapeutic targets. Unlike cerebrospinal fluid biomarkers that require a spinal tap, plasma biomarkers can be extracted from the blood, making their collection much less invasive and much more appealing for patients. In a study published in Annals of Clinical and Translational Neurology , a team led by investigators from Brigham and Women's Hospital describes the role of plasma ceramides in dementia and Alzheimer's disease (AD) and their potential as a blood-based biomarker.
Our findings indicate that circulating ceramide ratios may be useful predictors of future dementia risk and may have a role in predicting dementia at an early, preclinical stage, when the greatest opportunity for disease modification exists. However, these results will require replication in other cohorts." Emer McGrath, MD, PhD, associate neurologist in the Department of Neurology at the Brigham
Altered lipid metabolism is believed to play an important role in the development of dementia and Alzheimer's disease. Ceramides are a type of lipid belonging to the sphingolipid family and are thought to play an important role in lipid aggregation, inflammation, endothelial dysfunction and neuronal cell death. Recently, attention has focused on the possibility that the adverse effects of ceramides may be related to the relative proportions of circulating very-long-chain to long-chain fatty acyl chains, rather than simply due to elevated total ceramide levels. Very-long-chain fatty acyl ceramides are important for myelin function and may have a protective effect against dementia, while long-chain ceramide species are linked with deleterious pro-inflammatory and apoptotic effects. Related Stories
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology